Search research articles
Contact Us
Filters
Showing results (11-20 of 14) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 14 results.
Proceedings of the National Academy of Sciences of the United States of America
|
January 3, 1995
Erythrocyte lipids in triose-phosphate isomerase deficiency
S Hollán, I Dey, L Szollár, et al.
Cellular Signalling
|
October 17, 2001
Activation of Raf/ERK1/2 MAP kinase pathway is involved in GM-CSF-induced proliferation and survival but not in erythropoietin-induced differentiation of TF-1 cells
A Kolonics, Apáti A, J Jánossy, et al.
Annals of the New York Academy of Sciences
|
March 27, 2007
Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK
A Brózik, N P Casey, Cs Hegedus, et al.
British Journal of Pharmacology
|
September 30, 2009
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C Hegedus, C Ozvegy-Laczka, A Apáti, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 14) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 14 results.
Proceedings of the National Academy of Sciences of the United States of America
|
January 3, 1995
Erythrocyte lipids in triose-phosphate isomerase deficiency
S Hollán, I Dey, L Szollár, et al.
Cellular Signalling
|
October 17, 2001
Activation of Raf/ERK1/2 MAP kinase pathway is involved in GM-CSF-induced proliferation and survival but not in erythropoietin-induced differentiation of TF-1 cells
A Kolonics, Apáti A, J Jánossy, et al.
Annals of the New York Academy of Sciences
|
March 27, 2007
Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK
A Brózik, N P Casey, Cs Hegedus, et al.
British Journal of Pharmacology
|
September 30, 2009
Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
C Hegedus, C Ozvegy-Laczka, A Apáti, et al.
Page
of 2